

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Acne and Rosacea – Select Topical Agents Step Therapy Edit
<b>First Implementation Date:</b>	August 17, 2020
<b>Proposed Date:</b>	April 18, 2023
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of select topical agents for acne and rosacea.

**Why Issue Selected:** Acne is a chronic inflammatory condition presenting as comedones, papules, pustules, and nodules. Oil production, dead skin cells, clogged pores, and bacteria can all work together to cause acne. Acne affects about 50 million people in the United States, including 85% of adolescents and 12% of adult women. There are a variety of agents for the treatment of acne with a wide range of cost.

Rosacea is a chronic inflammatory condition, predominately affecting the facial skin and eyes, which typically presents any time after 30 years of age as flushing or redness on the cheeks, nose, chin, or forehead that may come and go. Rosacea is estimated to affect over 16 million people in the United States. There are a variety of topical and oral agents available for the treatment of rosacea.

Due to the large patient population affected and the variety of therapies available, it is fiscally advantageous for MO HealthNet to manage utilization of higher cost therapies. This edit will focus on expensive topical agents that are not currently being edited by other means.

**Program-Specific Information:**

Date Range FFS 1-1-2022 to 12-31-2022			
Drug	Claims	Spend	Avg Spend per Claim
AZELAIC ACID 15% GEL	227	\$13,310.17	\$58.64
CLINDAMYCIN PHOS 1% FOAM	7	\$81.40	\$11.63
CLINDAMYCIN PHOS 1% GEL	3	\$866.00	\$288.67
DAPSONE 5% GEL	66	\$11,286.29	\$171.00
DAPSONE 7.5% GEL PUMP	14	\$6,028.63	\$430.62
FIANCEA 15% FOAM	7	\$2,203.60	\$314.80
IVERMECTIN 1% CREAM	40	\$9,225.39	\$230.63
METRONIDAZOLE 0.75% CRM	837	\$39,252.95	\$46.90
METRONIDAZOLE 0.75% GEL	494	\$17,721.56	\$35.87
METRONIDAZOLE 0.75% LOT	6	\$644.34	\$107.39
METRONIDAZOLE 1% GEL	496	\$38,931.72	\$78.49
METRONIDAZOLE 1% GEL PUMP	35	\$2,161.40	\$61.75
MIRVASO 0.33% GEL PUMP	30	\$15,727.87	\$524.26

NORITATE 1% CREAM	3	\$5,906.97	\$1,968.99
RHOFADE 1% CREAM	23	\$12,390.64	\$538.72
SOD SULFACE-SULFUR 9-4.5% WASH	2	\$156.42	\$78.21
SOD SULFACE-SULF 9.8-4.8% CLSR	2	\$412.15	\$206.08

Type of Criteria:  Increased risk of ADE  
 Appropriate Indications

Preferred Drug List  
 Step Therapy Edit

Data Sources:  Only Administrative Databases

Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Select topical agents for acne and rosacea
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- For treatment of acne vulgaris (Aczone and Azelex agents):
  - Documented diagnosis of acne vulgaris in the past 2 years **AND**
  - Documented therapeutic trial of topical benzoyl peroxide and topical clindamycin or erythromycin (defined as 30 out of 90 days)
  - Clinical consultant review required for agents flagged as high cost therapies (see Appendix A)
- For treatment of rosacea (Finacea, Metrocream, Metrogel, Metro lotion, Mirvaso, Noritate, Rhofade, Rosadan, and Soolantra agents):
  - Claim is for topical azelaic acid 15% gel, metronidazole 1% gel, or metronidazole 0.75% cream or gel **OR**
  - Documented diagnosis of rosacea in the past 2 years **AND**
  - Documented therapeutic trial of azelaic acid 15% gel, metronidazole 1% gel, or metronidazole 0.75% cream or gel (defined as 30 out of 90 days)
  - Clinical consultant review required for agents flagged as high cost therapies (see Appendix A)

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:   
 MedWatch Form:

Progress Notes:   
 Other:

## Disposition of Edit

Denial: Exception code "0681" (Step Therapy Edit)  
 Rule Type: CE

## Default Approval Period

1 year

## Appendix A – High Cost Agents for Acne or Rosacea Therapy

Drug Description	Generic Equivalent
BP 10-1 WASH	SULFACETAMIDE SODIUM/SULFUR 10%-1%
BPO 6% FOAMING CLOTHS	BENZOYL PEROXIDE
CLINDACIN PAC KIT	CLINDAMYCIN PHOS/SKIN CLNSR 19 1% KIT
CLINDAGEL 1% GEL	CLINDAMYCIN PHOSPHATE
EVOCLIN 1% FOAM	CLINDAMYCIN PHOSPHATE
INOVA 4% EASY PAD	BENZOYL PEROXIDE/VITAMIN E MIXED
INOVA 4-1 EASY PAD	SALICYLIC ACID/BENZOYL PEROXIDE/ VITAMIN
INOVA 8% EASY PAD	BENZOYL PEROXIDE/VITAMIN E MIXED
INOVA 8-2 EASY PAD	SALICYLIC ACID/BENZOYL PEROXIDE/ VITAMIN
PLEXION 9.8-4.8% CLEANSER	SULFACETAMIDE SODIUM/SULFUR 9.8%-4.8%
ROSDAN 0.75% CREAM KIT	METRONIDAZOLE/SKIN CLEANSR #23
ROSDAN 0.75% GEL KIT	METRONIDAZOLE/SKIN CLEANSR #23
ROSULA 10%-5% CLOTHS	SULFACETAMIDE SODIUM/SULFUR 10-5%
SOD SULFACETAMIDE-SULFUR LOT	SULFACETAMIDE SOD/SULFUR 10-5%(W/W)
SSS 10-5 FOAM	SULFACETAMIDE SODIUM/SULFUR 10%-5%
SUMADAN 9%-4.5% WASH	SULFACETAMIDE SODIUM/SULFUR 9 %-4.5 %
SUMAXIN CLEANSING PADS	SULFACETAMIDE SODIUM/SULFUR 10%-4%

## References

- IPD Analytics. Dermatology: Acne. Accessed January 19, 2023.
- IPD Analytics. Dermatology: Rosacea. Accessed January 19, 2023.
- Maier, Lisa E. (2021). Management of rosacea. UpToDate. Accessed January 19, 2023.
- Graber, Emmy. (2021). Acne vulgaris: Overview of management. UpToDate. Accessed January 19, 2023.
- Zaenglein, A, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74: 945-73. <http://dx.doi.org/10.1016/j.jaad.2015.12.037>
- National Institute for health and Care Excellence (NICE). Acne vulgaris: management. [Acne vulgaris: management \(nice.org.uk\)](https://www.nice.org.uk/guidance/NG107). June 2021. Accessed February 3, 2022.
- Schaller, M, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. British Journal of Dermatology. August 7, 2019. <https://doi.org/10.1111/bjd.18420>
- Hampton, P J, et al. British Association of Dermatologists guidelines for the management of people with rosacea 2021. Br J Dermatol. 2021;185(4):725-735. doi:10.1111/bjd.20485. [British Association of Dermatologists guidelines for the management of people with rosacea 2021\\* - Hampton - 2021 - British Journal of Dermatology - Wiley Online Library](https://onlinelibrary.wiley.com/doi/10.1111/bjd.20485)
- Thiboutot, D, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol 2020; 82:1501-10. <https://doi.org/10.1016/j.jaad.2020.01.077>